BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 03, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/30 cls
AMAG Pharmaceuticals Inc. Baird Christopher Raymond Price target Market outperform -6% $34.15
(NASDAQ:AMAG) Jefferies Eun Yang Price target Hold
Leerink Joseph Schwartz Price target Market outperform
Needham Mark Monane Price target Buy
Raymond lowered his target to $40 from $53 after AMAG reported 1Q10 sales of Feraheme ferumoxytol of $13.1M, below his and the consensus estimate of $16M. Raymond noted he believed last quarter's sales were...

Read the full 755 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >